Skip to main content

Table 9 The risk of bias and study quality for each fibromyalgia review

From: A comparison of two assessment tools used in overviews of systematic reviews: ROBIS versus AMSTAR-2

Fibromyalgia AMSTAR-2 ROBIS
Multiple CAM therapies
Holdcraft 2003 [14] CL Low
 Baronowsky 2009 [15] CL High
 Terhorst 2011, 2012 [16, 17] CL High
 De Silva 2010 [18] CL High
Homoeopathy
Perry 2010 [19] CL Low
 Boehm 2014 [20] CL High
Chiropractic treatment
 Ernst 2009 [21] CL Unclear
Acupuncture
Mayhew and Ernst 2007 [22] CL Low
Daya 2007 [23] CL Low
Langhorst 2010 [24] CL Low
 Martin-Sanchez 2009 [25] CL High
Cao 2013 [26] CL Low
 Deare 2013 [13] LOW Low
 Yang 2014 [27] CL High
Herbal medicines
de Souza Nascimento 2013 [28] CL Low
  1. When AMSTAR-2 is low, this should correspond to ROBIS being of high risk of bias. The italicised reviews show discrepancies between the overall rating of quality/bias